Effective prediction methods for monitoring the risk of recurrence of colorectal cancer liver metastasis (CRLM) and guiding postoperative adjuvant treatment (ACT) are currently lacking.
This study aimed to evaluate the value of postoperative dynamic circulating tumor DNA (ctDNA) monitoring in guiding ACT and predicting recurrence compared with other clinicopathological factors.
